Literature DB >> 16928753

Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction.

Heidi Barth1, Eva K Schnober, Fuming Zhang, Robert J Linhardt, Erik Depla, Bertrand Boson, Francois-Loic Cosset, Arvind H Patel, Hubert E Blum, Thomas F Baumert.   

Abstract

Cellular binding and entry of hepatitis C virus (HCV) are the first steps of viral infection and represent a major target for antiviral antibodies and novel therapeutic strategies. We have recently demonstrated that heparan sulfate (HS) plays a key role in the binding of HCV envelope glycoprotein E2 to target cells (Barth et al., J. Biol. Chem. 278:41003-41012, 2003). In this study, we characterized the HCV-HS interaction and analyzed its inhibition by antiviral host immune responses. Using recombinant envelope glycoproteins, virus-like particles, and HCV pseudoparticles as model systems for the early steps of viral infection, we mapped viral and cellular determinants of HCV-HS interaction. HCV-HS binding required a specific HS structure that included N-sulfo groups and a minimum of 10 to 14 saccharide subunits. HCV envelope binding to HS was mediated by four viral epitopes overlapping the E2 hypervariable region 1 and E2-CD81 binding domains. In functional studies using HCV pseudoparticles, we demonstrate that HCV binding and entry are specifically inhibited by highly sulfated HS. Finally, HCV-HS binding was markedly inhibited by antiviral antibodies derived from HCV-infected individuals. In conclusion, our results demonstrate that binding of the viral envelope to a specific HS configuration represents an important step for the initiation of viral infection and is a target of antiviral host immune responses in vivo. Mapping of viral and cellular determinants of HCV-HS interaction sets the stage for the development of novel HS-based antiviral strategies targeting viral attachment and entry.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16928753      PMCID: PMC1641783          DOI: 10.1128/JVI.00941-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

Review 1.  Molecular diversity of heparan sulfate.

Authors:  J D Esko; U Lindahl
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

2.  Probing the interaction of dengue virus envelope protein with heparin: assessment of glycosaminoglycan-derived inhibitors.

Authors:  R M Marks; H Lu; R Sundaresan; T Toida; A Suzuki; T Imanari; M J Hernáiz; R J Linhardt
Journal:  J Med Chem       Date:  2001-06-21       Impact factor: 7.446

3.  Cell surface heparan sulfate is a receptor for human herpesvirus 8 and interacts with envelope glycoprotein K8.1.

Authors:  A Birkmann; K Mahr; A Ensser; S Yağuboğlu; F Titgemeyer; B Fleckenstein; F Neipel
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Interaction of classical swine fever virus with membrane-associated heparan sulfate: role for virus replication in vivo and virulence.

Authors:  M M Hulst; H G van Gennip; A C Vlot; E Schooten; A J de Smit; R J Moormann
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

5.  Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines.

Authors:  Sabine Wellnitz; Bettina Klumpp; Heidi Barth; Susumu Ito; Erik Depla; Jean Dubuisson; Hubert E Blum; Thomas F Baumert
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

6.  Reconstitution of hepatitis C virus envelope glycoproteins into liposomes as a surrogate model to study virus attachment.

Authors:  Michel Lambot; Stéphanie Frétier; Anne Op De Beeck; Brigitte Quatannens; Sophie Lestavel; Veronique Clavey; Jean Dubuisson
Journal:  J Biol Chem       Date:  2002-04-05       Impact factor: 5.157

Review 7.  Heparin and heparan sulfate: structure and function.

Authors:  Dallas L Rabenstein
Journal:  Nat Prod Rep       Date:  2002-06       Impact factor: 13.423

8.  Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles.

Authors:  Reginald F Clayton; Ania Owsianka; Jim Aitken; Susan Graham; David Bhella; Arvind H Patel
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

9.  Characterization of a heparan sulfate octasaccharide that binds to herpes simplex virus type 1 glycoprotein D.

Authors:  Jian Liu; Zach Shriver; R Marshall Pope; Suzanne C Thorp; Michael B Duncan; Ronald J Copeland; Christina S Raska; Keiichi Yoshida; Roselyn J Eisenberg; Gary Cohen; Robert J Linhardt; Ram Sasisekharan
Journal:  J Biol Chem       Date:  2002-06-21       Impact factor: 5.157

10.  Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption.

Authors:  Raphaële Germi; Jean-Marc Crance; Daniel Garin; Josette Guimet; Hugues Lortat-Jacob; Rob W H Ruigrok; Jean-Pierre Zarski; Emmanuel Drouet
Journal:  J Med Virol       Date:  2002-10       Impact factor: 2.327

View more
  75 in total

1.  Specific interaction of the envelope glycoproteins E1 and E2 with liver heparan sulfate involved in the tissue tropismatic infection by hepatitis C virus.

Authors:  Fumi Kobayashi; Shuhei Yamada; Shuhei Taguwa; Chikako Kataoka; Satomi Naito; Yoshiki Hama; Hideki Tani; Yoshiharu Matsuura; Kazuyuki Sugahara
Journal:  Glycoconj J       Date:  2012-06-03       Impact factor: 2.916

2.  EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.

Authors:  Joachim Lupberger; Mirjam B Zeisel; Fei Xiao; Christine Thumann; Isabel Fofana; Laetitia Zona; Christopher Davis; Christopher J Mee; Marine Turek; Sebastian Gorke; Cathy Royer; Benoit Fischer; Muhammad N Zahid; Dimitri Lavillette; Judith Fresquet; François-Loïc Cosset; S Michael Rothenberg; Thomas Pietschmann; Arvind H Patel; Patrick Pessaux; Michel Doffoël; Wolfgang Raffelsberger; Olivier Poch; Jane A McKeating; Laurent Brino; Thomas F Baumert
Journal:  Nat Med       Date:  2011-04-24       Impact factor: 53.440

3.  Identification of a dendrimeric heparan sulfate-binding peptide that inhibits infectivity of genital types of human papillomaviruses.

Authors:  Manuela Donalisio; Marco Rusnati; Andrea Civra; Antonella Bugatti; Donatella Allemand; Giovanna Pirri; Andrea Giuliani; Santo Landolfo; David Lembo
Journal:  Antimicrob Agents Chemother       Date:  2010-07-19       Impact factor: 5.191

4.  Attachment and Postattachment Receptors Important for Hepatitis C Virus Infection and Cell-to-Cell Transmission.

Authors:  Huahao Fan; Luhua Qiao; Kyung-Don Kang; Junfen Fan; Wensheng Wei; Guangxiang Luo
Journal:  J Virol       Date:  2017-06-09       Impact factor: 5.103

5.  Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate.

Authors:  Jieyun Jiang; Wei Cun; Xianfang Wu; Qing Shi; Hengli Tang; Guangxiang Luo
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

Review 6.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

7.  Contribution of redox status to hepatitis C virus E2 envelope protein function and antigenicity.

Authors:  Emmanuel Fenouillet; Dimitri Lavillette; Silvia Loureiro; George Krashias; Guillemette Maurin; François-Loïc Cosset; Ian M Jones; Rym Barbouche
Journal:  J Biol Chem       Date:  2008-07-30       Impact factor: 5.157

8.  Tetraspanin CD81 is required for Listeria monocytogenes invasion.

Authors:  To Nam Tham; Edith Gouin; Eric Rubinstein; Claude Boucheix; Pascale Cossart; Javier Pizarro-Cerda
Journal:  Infect Immun       Date:  2009-11-09       Impact factor: 3.441

Review 9.  Heparanase and hepatocellular carcinoma: promoter or inhibitor?

Authors:  Shuo Dong; Xiong-Zhi Wu
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

Review 10.  Neutralizing antibodies in hepatitis C virus infection.

Authors:  Mirjam-B Zeisel; Samira Fafi-Kremer; Isabel Fofana; Heidi Barth; Francoise Stoll-Keller; Michel Doffoel; Thomas-F Baumert
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.